Trial Profile
A Therapeutic Trial for Safety and Preliminary Efficacy of the Combination of Axitinib and Seleniomethionine (SLM) for Adult Patients With Advanced Metastatic Clear Cell Renal Cell Carcinoma (CCRCC)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Axitinib (Primary) ; Selenomethionine (Primary)
- Indications Renal cell carcinoma; Sarcoma
- Focus Adverse reactions
- Acronyms Bench to bedside
- 23 Aug 2023 Planned End Date changed from 1 Dec 2023 to 17 May 2026.
- 22 Aug 2023 Status changed from recruiting to active, no longer recruiting.
- 20 Jul 2023 Planned End Date changed from 1 Jun 2023 to 1 Dec 2023.